Communicators

 TORONTO, ON - January 27, 2021 - Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (FRA:20MP) is pleased to announce it has executed an agreement to conduct its Bio Safety Level 4 (“BSL-4”) lab study of COVID-19 viral clearance in transgenic mice designed to prove the superiority of the Company’s solubilized Ivermectin technology versus commercially available oral form in speed and efficacy of viral clearance. The agreement was signed January 26, 2021. “This is a very significant project for MVMD and it will clearly demonstrate how our solubility technology ... [ more ]